PharmAsia News India Pharma Roundup: Jubilant Organosys, Drug Price Cuts, Pharma Advisory Forum, Ranbaxy
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - India's Jubilant Organosys' $225 million all-cash deal for Canada's Draxis Health provides the company a path to consolidate contract manufacturing in North America with a contract in hand to launch a generic version of Johnson & Johnson's imaging agent Cardiolite in 2008 and time to mull whether to retain the company's currently high margin but increasingly competitive radiopharmaceutical business, Kotak Institutional Equities said